© 2021 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2021 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
June 09, 2021
Learn how to approach palliative care discussions with both physicians and patients.
June 08, 2021
The second-generation 4-1BB bi-specific CAR T-cell therapy was efficacious and safe in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
June 07, 2021
Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.
June 02, 2021
The FDA has granted a breakthrough therapy designation to teclistamab for the treatment of patients with relapsed/refractory multiple myeloma.
May 30, 2021
Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.
May 29, 2021
Melphalan flufenamide was noninferior to pomalidomide in patients with relapsed or refractory myeloma.
May 27, 2021
The FDA has granted priority review to the biologics license application for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma.
May 26, 2021
The FDA has accepted a biologics license application for ublituximab in combination with umbralisib in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia.
May 24, 2021
Adding the antibody-drug conjugate to the frontline treatment of patients with pediatric high-risk Hodgkin lymphoma resulted in favorable clinical outcomes.
May 14, 2021
Whole-genome sequencing may hold the answers for patients with myeloma precursor conditions.